2019 Tufts CEVR’s Cost-Effectiveness Analysis Paper of the Year Award Announced

Date: July 22, 2020

Tufts Medical Center’s Center for the Evaluation of Value and Risk in Health (CEVR) is pleased to announce the winner of our second annual Cost-Effectiveness Analysis (CEA) Paper of the Year Award. Under the leadership of Dr. Lisa Prosser, a Professor and Director of the Susan B. Meister Child Health Evaluation and Research Center at University of Michigan, researchers from the University of Michigan and Centers for Disease Control and Prevention conducted a cost-effectiveness analysis of a recently-approved recombinant vaccine for herpes zoster (Shingrix, GlaxoSmithKline). The analysis was intended to inform recommendations from the Advisory Committee on Immunization Practices and was selected for its policy relevance and exemplary methodological quality.

Dr. Prosser’s paper was chosen from a competitive pool of 22 high-quality submissions. Each paper underwent blinded review by CEVR faculty, who evaluated the submissions for methodological quality, timeliness, and potential influence on policy or clinical decision-making. The three papers with the highest faculty ratings were then reviewed by CEVR’s CEA Registry Advisory Board using the same criteria. The two other finalists included a cost-effectiveness analysis of screening donated blood for Zika virus in the United States, and canakinumab for the prevention of recurrent cardiovascular events, respectively.

CEVR will announce a call for 2020 submissions in the fall of this year.

Winning paper

Prosser LA, Harpaz R, Rose AM, et al. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Ann Intern Med. 2019;170(6):380-388. doi:10.7326/M18-2347


Russell WA, Stramer SL, Busch MP, Custer B. Screening the Blood Supply for Zika Virus in the 50 U.S. States and Puerto Rico: A Cost-Effectiveness Analysis. Ann Intern Med. 2019;170(3):164-174. doi:10.7326/M18-2238

Sehested TSG, Bjerre J, Ku S, et al. Cost-effectiveness of Canakinumab for Prevention of Recurrent Cardiovascular Events. JAMA Cardiol. 2019;4(2):128-135. doi:10.1001/jamacardio.2018.4566

About the CEA Registry Advisory Board

The CEA Board is composed of senior leaders in health policy who represent diverse perspectives in health care. Current members are listed below.

  • Michael Drummond, PhD, Professor of Health Economics, Centre for Health Economics, University of York
  • Dan Greenberg, PhD, Professor and Chairman, Department of Health Systems Management, School of Public Health, Faculty of Health Sciences, The Guildford Glazer Faculty of Business and Management, Ben-Gurion University of the Negev
  • Kakoli Roy, PhD, Chief Economist, Office of the Associate Director for Policy, Centers for Disease Control and Prevention
  • Edmund Pezalla, MD, Founder and CEO of Enlightenment Bioconsult
  • Chris Pashos, PhD, Independent Advisor and Consultant: Enhancing drug development and commercialization via RWE & HEOR to improve access

More News Articles